Clinical Trials Logo

Multiple Myeloma in Relapse clinical trials

View clinical trials related to Multiple Myeloma in Relapse.

Filter by:

NCT ID: NCT01083602 Completed - Clinical trials for Refractory Multiple Myeloma

Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma

MACS1271
Start date: June 2010
Phase: Phase 2
Study type: Interventional

This study is designed to assess the effectiveness of the combination of Panobinostat plus Bortezomib and Dexamethasone in patients with relapsed and bortezomib refractory Multiple Myeloma.

NCT ID: NCT00401011 Completed - Multiple Myeloma Clinical Trials

Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients

Start date: August 2006
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II study of perifosine in combination with bortezomib—with or without dexamethasone—for patients with relapsed or refractory multiple myeloma previously treated with bortezomib. The current protocol will enroll patients with relapsed or refractory multiple myeloma who have been previously treated with bortezomib. The patients will be treated with perifosine, 50 mg or 100 mg qhs, in combination with bortezomib to determine if there is any preliminary evidence that the addition of perifosine improves the outcome for these patients. Previous treatment with perifosine will be allowed in this study. Patients progressing on treatment with perifosine and bortezomib will receive dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 18, and 19 of each 21-day cycle in addition to bortezomib and perifosine.